Overview

Mylan Insulin Glargine Study

Status:
Active, not recruiting

Trial end date:
2018-12-01

Target enrollment:

Participant gender:

Summary

The aim of this study is to demonstrate similar efficacy and safety between MYL-1501D products produced from two manufacturing processes (Process V and Process VI) in combination with insulin lispro in patients with type 1 diabetes mellitus (T1DM).

Phase:

Phase 3

Details

Lead Sponsor:

Mylan Inc.

Collaborator:

Mylan GmbH

Treatments:

MYL-1501D